The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Top Cited Papers
Open Access
- 9 February 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Microbiology
- Vol. 7 (3), 226-236
- https://doi.org/10.1038/nrmicro2090
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- SARS coronavirus and innate immunityVirus Research, 2008
- Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infectionVaccine, 2008
- Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail DeletedJournal of Virology, 2007
- Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivityBiochemical and Biophysical Research Communications, 2007
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesProceedings of the National Academy of Sciences of the United States of America, 2007
- Synthetic Reconstruction of Zoonotic and Early Human Severe Acute Respiratory Syndrome Coronavirus Isolates That Produce Fatal Disease in Aged MiceJournal of Virology, 2007
- Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)Vaccine, 2007
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences of the United States of America, 1994